VI International Summit
Heart Failure and Pulmonary Hypertension Management in the Polypharmacy and Device Era
Heart Failure Review 2021
November 29 - December 04, 2021
Alejandro Barbagelata, MD, FAHA, FSCAI, FICA, MSAC
Dr Barbagelata is an invasive cardiologist with Heart Failure longstanding expertise. He was past director of the Heart failure, assist devices and Transplant at University of Texas medical branch. Professor of
Medicine/Cardiology Duke University
School of Medicine and Board of Directors of DUCCS (Duke University CardiovascularSociety). Member of the InternationalSpeaker Bureau of the American Heart Association. He Co-direct the Heart Failure program at the Catholic University in Buenos Aires and has privileges in several centers in private practice
Sergio V. Perrone, MD, MTFACC, MTSACD
Dr Perrone was instrumental in generating the largest Heart Failure and Transplant program in south america in the early 80s and is an opinion leader in the region. He co-direct the heart failure program at the catholic university and direct the heart failure and pulmonary hypertension journal. Also direct the heart failure and Tx program in El Cruce Hospital and Fleni Institute
JOHN MC MURRAY
New Trials in Heart Failure.Where are we at the end of 2020
Iron Deficiency in Heart Failure
Quadruple Therapy as the new standard of care in heart failure with reduced EF
VAD-Destination Therapy or Bridge?
Ventricular Assist Devices. Present and future
pre and post capillary pulmonary hypertension. upfront therapy?
Drug and devices in the treatment of hfpef. new options
With arnis and sglt2, how can we manage polipharmacy in hf?
MARCELO DI CARLI
How imaging change the treatment paradigm in cardiomyopathies
support in pulmonary hypertension in advanced right heart failure
End stage hf patients keep need to keep or remove CRT-d?
Lic. Sofia Barbagelata